Table 3.

The clinical relevance of Epi‐LumB and Epi‐Basal tumors, defined according to selected proxy markers, analyzed with respect to parameters of clinical staging (tumor size and nodal metastasis status) and degree of differentiation (histological grade).

Tumor size	T1a‐c	T2 – T3	Total
Epi‐LumB	18 (26%)	52 (74%)	68 (100%)
Epi‐Basal	17 (30%)	40 (70%)	56 (100%)
Other	46 (52%)	42 (48%)	88 (100%)
			X 2 = 13.7; P = 0.0010
Nodal metastases	Negative	Positive	Total
Epi‐LumB	23 (35%)	43 (65%)	64 (100%)
Epi‐Basal	19 (36%)	34 (64%)	52 (100%)
Other	37 (49%)	38 (51%)	75 (100%)
			X 2 = 3.8; P = 0.15
Histological grading	1+/2+	3+	Total
Epi‐LumB	12 (32%)	25 (67%)	35 (100%)
Epi‐Basal	11 (32%)	23 (68%)	33 (100%)
Other	47 (78%)	13 (22%)	54 (100%)
			X 2 = 27.6; P < 0.0001